Please notice!
This website uses cookies to provide necessary site functionality and improve your online experience. By using this website, you agree to the use of cookies as outlined in the
Privacy Statement
.

As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is
committed to providing our customers around the world with the highest quality products.
In addition to direct selling in more than 20 countries in North America, Europe and
Asia/Pacific, Miltenyi Biotec also provides support for our customers through an
extensive distributor network covering dozens of additional countries.

As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is
committed to providing our customers around the world with the highest quality products.
In addition to direct selling in more than 20 countries in North America, Europe and
Asia/Pacific, Miltenyi Biotec also provides support for our customers through an
extensive distributor network covering dozens of additional countries.

CD141 (BDCA-3) antibodies, human

Clone AD5-14H12 recognizes the human CD141 (BDCA-3) antigen which is expressed at high levels on a minor subpopulation of human myeloid dendritic cells (about 0.02% of blood leukocytes). CD141 (BDCA‑3)

high

blood dendritic cells are CD11c

dim

, CD123

–

, CD4

+

, Lin

–

, CD45RO

+

, CD2

–

, and CD16

–

. They express myeloid lineage markers, such as CD13 and CD33, and have a monocytoid morphology. Unlike CD1c (BDCA-1)

+

blood dendritic cells, CD141 (BDCA-3)

high

blood dendritic cells lack expression of CD2 and Fc receptors such as CD32, CD64, or FcεRI. CD141 (BDCA-3) is also present at very low levels on CD14

+

monocytes, granulocytes, CD303 (BDCA‑2)

+

CD304 (BDCA-4/Neuropilin-1)

+

plasmacytoid and CD1c (BDCA-1)

+

myeloid dendritic cells. CD141 (BDCA‑3)

high

CD1c (BDCA-1)

–

myeloid dendritic cells have been designated type-2 myeloid dendritic cells (MDC2s). CD141 is also known as thrombomodulin; thrombomodulin mediates co-agglutination by interaction with thrombin and protein C, though nothing is known about its function on MDC2s.

Figure 1

Human peripheral blood mononuclear cells (PBMCs) were stained with CD141 (BDCA-3) antibodies as well as with Anti-CLEC9A and CD45 antibodies and analyzed by flow cytometry using the MACSQuant

®

Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. For all other conjugates the FcR Blocking Reagent has been used to avoid Fc receptor–mediated antibody labeling. A pre-gate of CD45

+

cells was used. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.